`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`
`Plaintiff/Counter-Defendant,
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`
`
`Defendant/Counter-Claimant.
`
`
` CIVIL NO. 1:22-CV-61
`
`
` (KLEEH)
`
`MEMORANDUM OPINION AND ORDER DENYING MYLAN’S SECOND
`MOTION TO AMEND [ECF NO. 505] AND GRANTING REGENERON’S
`MOTION FOR JUDGMENT ON THE PLEADINGS [ECF NO. 175]
`
`Pending before the Court is Mylan’s second motion to amend
`
`its answer, defenses, and counterclaims [ECF No. 505], which
`relates to Regeneron’s motion for judgment on the pleadings [ECF
`No. 175]. For the reasons discussed herein, the Court DENIES
`Mylan’s motion and GRANTS Regeneron’s.
`Rule 15 of the Federal Rules of Civil Procedure provides that
`“a party may amend its pleading only with the opposing party’s
`written consent or the court’s leave” and that “[t]he court should
`freely give leave when justice so requires.” Leave to amend
`“should be denied only when the amendment would be prejudicial to
`the opposing party, there has been bad faith on the part of the
`moving party, or the amendment would have been futile.” Sciolino
`v. Newport News, 480 F.3d 642, 651 (4th Cir. 2007) (citation
`omitted). The Court finds that Mylan’s proposed amendment would
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 524 Filed 06/06/23 Page 2 of 4 PageID #: 41445
`REGENERON V. MYLAN
`
`
`
`
`
` 1:22-CV-61
`MEMORANDUM OPINION AND ORDER DENYING MYLAN’S SECOND
`MOTION TO AMEND [ECF NO. 505] AND GRANTING REGENERON’S
`MOTION FOR JUDGMENT ON THE PLEADINGS [ECF NO. 175]
`
`be prejudicial to Regeneron due to its untimeliness and the volume
`of new allegations proposed. For these reasons and the reasons
`discussed during the pretrial conference on May 30, 2023, the Court
`DENIES Mylan’s second motion to amend [ECF No. 505].
`
`As for Regeneron’s motion for judgment on the pleadings, the
`Court agrees with Regeneron that Mylan has failed to adequately
`plead its inequitable conduct defenses and counterclaims. The
`judicially-created doctrine of inequitable conduct renders a
`patent unenforceable when an alleged infringer demonstrates that
`the patent holder engaged in “egregious affirmative acts of
`misconduct” intended to deceive the PTO or failed to disclose
`material information to the PTO in seeking the patent. Therasense,
`Inc. v. Becton, Dickinson & Co., 649 F.3d 1276, 1287 (Fed. Cir.
`2011). A party alleging inequitable conduct as either a defense
`or a counterclaim must plead the circumstances of the conduct with
`particularity. Central Admixture Pharmacy Servs., Inc. v.
`Advanced Cardiac Solutions, P.C., 482 F.3d 1347, 1356–57 (Fed.
`Cir. 2007). The Federal Circuit requires that the pleading party
`“identif[y] . . . the specific who, what, when, where, and how of
`the material misrepresentation or omission committed before the
`PTO.” Exergen Corp. v. Wal-Mart Stores, Inc., 575 F.3d 1312, 1327
`(Fed. Cir. 2009). The pleading party must allege facts supporting
`
`
`
`2
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 524 Filed 06/06/23 Page 3 of 4 PageID #: 41446
`REGENERON V. MYLAN
`
`
`
`
`
` 1:22-CV-61
`MEMORANDUM OPINION AND ORDER DENYING MYLAN’S SECOND
`MOTION TO AMEND [ECF NO. 505] AND GRANTING REGENERON’S
`MOTION FOR JUDGMENT ON THE PLEADINGS [ECF NO. 175]
`
`an inference “that a specific individual (1) knew of the withheld
`material information or of the falsity of the material
`misrepresentation, and (2) withheld or misrepresented this
`information with a specific intent to deceive the PTO.” Id. at
`1328–29.
`Specifically, the Court finds that Mylan has failed to plead
`intent. It has not sufficiently pled the “who, what, when, where,
`and how.” See Exergen, 575 F.3d at 1327. Even if Mylan had
`satisfied intent, Mylan’s allegations also fail because the cited
`statements were attorney argument. “While the law prohibits
`genuine misrepresentations of material fact, a prosecuting
`attorney is free to present argument in favor of patentability
`without fear of committing inequitable conduct.” Rothman v. Target
`Corp., 556 F.3d 1310, 1328–29 (Fed. Cir. 2009). As such, Mylan
`has not sufficiently pled its inequitable conduct defenses and
`counterclaims, and Regeneron’s motion for judgment on the
`pleadings is GRANTED [ECF No. 175].
`It is so ORDERED.
`
`The Clerk is DIRECTED to transmit copies of this Order to
`
`counsel of record.
`
`
`
`
`
`3
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 524 Filed 06/06/23 Page 4 of 4 PageID #: 41447
`REGENERON V. MYLAN
`
`
`
`
`
` 1:22-CV-61
`MEMORANDUM OPINION AND ORDER DENYING MYLAN’S SECOND
`MOTION TO AMEND [ECF NO. 505] AND GRANTING REGENERON’S
`MOTION FOR JUDGMENT ON THE PLEADINGS [ECF NO. 175]
`DATED: June 6, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`____________________________
`THOMAS S. KLEEH, CHIEF JUDGE
`NORTHERN DISTRICT OF WEST VIRGINIA
`
`
`
`4
`
`